Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Abbott Laboratories (ABT) A Good Stock To Buy?

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the best-performing investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish on. One of their picks is Abbott Laboratories (NYSE:ABT), so let’s take a closer look at the sentiment that surrounds it in the current quarter.

Is Abbott Laboratories (NYSE:ABT) going to take off soon? Hedge funds are in a pessimistic mood. The number of bullish hedge fund positions dropped by 1 in recent months. Our calculations also showed that ABT isn’t among the 30 most popular stocks among hedge funds. ABT was in 53 hedge funds’ portfolios at the end of the third quarter of 2018. There were 54 hedge funds in our database with ABT holdings at the end of the previous quarter.

Hedge funds’ reputation as shrewd investors has been tarnished in the last decade as their hedged returns couldn’t keep up with the unhedged returns of the market indices. Our research has shown that hedge funds’ small-cap stock picks managed to beat the market by double digits annually between 1999 and 2016, but the margin of outperformance has been declining in recent years. Nevertheless, we were still able to identify in advance a select group of hedge fund holdings that outperformed the market by 18 percentage points since May 2014 through December 3, 2018 (see the details here). We were also able to identify in advance a select group of hedge fund holdings that underperformed the market by 10 percentage points annually between 2006 and 2017. Interestingly the margin of underperformance of these stocks has been increasing in recent years. Investors who are long the market and short these stocks would have returned more than 27% annually between 2015 and 2017. We have been tracking and sharing the list of these stocks since February 2017 in our quarterly newsletter.

Phill Gross, Adage Capital Management

We’re going to analyze the fresh hedge fund action encompassing Abbott Laboratories (NYSE:ABT).

What have hedge funds been doing with Abbott Laboratories (NYSE:ABT)?

At Q3’s end, a total of 53 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -2% from one quarter earlier. The graph below displays the number of hedge funds with bullish position in ABT over the last 13 quarters. So, let’s find out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

No of Hedge Funds with ABT Positions

The largest stake in Abbott Laboratories (NYSE:ABT) was held by Diamond Hill Capital, which reported holding $653.4 million worth of stock at the end of September. It was followed by Adage Capital Management with a $202.5 million position. Other investors bullish on the company included Citadel Investment Group, Sirios Capital Management, and Partner Fund Management.

Seeing as Abbott Laboratories (NYSE:ABT) has witnessed declining sentiment from the entirety of the hedge funds we track, it’s easy to see that there was a specific group of money managers that elected to cut their entire stakes last quarter. It’s worth mentioning that Matthew Tewksbury’s Stevens Capital Management sold off the largest position of the 700 funds watched by Insider Monkey, worth an estimated $35.1 million in stock. Jeremy Green’s fund, Redmile Group, also cut its stock, about $27.4 million worth. These moves are important to note, as aggregate hedge fund interest fell by 1 funds last quarter.

Let’s now review hedge fund activity in other stocks similar to Abbott Laboratories (NYSE:ABT). These stocks are Philip Morris International Inc. (NYSE:PM), 3M Company (NYSE:MMM), Honeywell International Inc. (NYSE:HON), and China Petroleum & Chemical Corporation (NYSE:SNP). This group of stocks’ market values are closest to ABT’s market value.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
PM 41 2897202 -2
MMM 34 355750 1
HON 47 2452575 -2
SNP 13 284383 -1
Average 33.75 1497478 -1

View table here if you experience formatting issues.

As you can see these stocks had an average of 33.75 hedge funds with bullish positions and the average amount invested in these stocks was $1.50 billion. That figure was $1.70 billion in ABT’s case. Honeywell International Inc. (NYSE:HON) is the most popular stock in this table. On the other hand China Petroleum & Chemical Corp (NYSE:SNP) is the least popular one with only 13 bullish hedge fund positions. Compared to these stocks Abbott Laboratories (NYSE:ABT) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...